Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,523 across all filing types
Latest filing 2018-08-03 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 July 2018
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/07/2018, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related capital changes. The content focuses on share capital changes and movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting monthly share capital movements, typical for compliance with exchange rules. It is not an annual or quarterly report, earnings release, or management discussion. It is not a proxy, AGM material, or voting result announcement. The document is a regulatory announcement about share capital movements, fitting best under Regulatory Filings (RNS).
2018-08-03 English
VOLUNTARY ANNOUNCEMENT - "STATE KEY LABORATORY FOR NOVEL PHARMACEUTICAL PREPARATIONS AND EXCIPIENTS" RATED AS EXCELLENT CLASS OF STATE KEY LABORATORY
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the excellent rating of their State Key Laboratory by the Ministry of Science and Technology. It contains no financial data, no regulatory form references, no voting results, no management changes, no earnings or financial statements. The document is an announcement of a non-financial achievement and does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a general regulatory announcement about a corporate achievement. The document length is 4535 characters, which is relatively short and the content is an announcement rather than a report. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2018-07-23 English
VOLUNTARY ANNOUNCEMENT - PRODUCT CO-DEVELOPMENT AND STRATEGIC COLLABORATION AGREEMENT
Capital/Financing Update Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding a product co-development and strategic collaboration agreement with Shanghai Junshi Biosciences. It details the terms of the agreement, responsibilities of each party, milestone payments, and intellectual property rights. There is no financial data, no regulatory filing form mentioned, no voting results, no management changes, no earnings or annual report content. The document is an announcement of a strategic collaboration and product development agreement, which fits best under Capital/Financing Update (CAP) as it relates to strategic business collaboration and potential future financial impact. The document length is 4495 characters, which is a full announcement rather than a brief note or a report publication announcement. Therefore, the classification is CAP with high confidence.
2018-07-10 English
VOLUNTARY ANNOUNCEMENT - THE GROUP'S INVESTIGATIONAL NEW DRUG "CSPCHA115" WAS GRANTED CLINICAL TRIAL APPROVAL BY THE U.S. FDA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the Board of Directors of CSPC Pharmaceutical Group Limited regarding the U.S. FDA approval of an Investigational New Drug (IND) application for a new drug developed by the company. It is an announcement of a regulatory milestone related to clinical trial approval, not a financial report, management change, or shareholder meeting material. The document is relatively short (2895 characters) and serves as a public disclosure of a significant event rather than a detailed report or filing. There is no indication of financial data, voting results, or other report types. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-07-10 English
VOLUNTARY ANNOUNCEMENT - PASSING OF CONSISTENCY EVALUATION FOR THE GROUP'S "CAPTOPRIL TABLETS"
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the passing of a regulatory consistency evaluation for their drug 'Captopril Tablets'. It is an announcement of an event related to product approval and does not contain financial data, management discussion, voting results, or any detailed report content. The document is short (2107 characters) and serves as a public disclosure of a regulatory milestone rather than a financial or governance report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Board/Management Information. It is not a certification or legal proceeding update either. Given the nature and length, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2018-07-10 English
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Board/Management Information Classification · 95% confidence The document lists the members of the board of directors, their roles, and committee memberships. It focuses on governance structure and board composition without financial data or report content. This matches the description of Board/Management Information (MANG), which covers announcements of changes or details about the company's board or senior management. The document is short and does not contain financial statements or other report types. Therefore, the appropriate classification is MANG.
2018-07-09 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.